- Politics
- Diversity, equity and inclusion
- Financial Decision Making
- Telehealth
- Patient Experience
- Leadership
- Point of Care Tools
- Product Solutions
- Management
- Technology
- Healthcare Transformation
- Data + Technology
- Safer Hospitals
- Business
- Providers in Practice
- Mergers and Acquisitions
- AI & Data Analytics
- Cybersecurity
- Interoperability & EHRs
- Medical Devices
- Pop Health Tech
- Precision Medicine
- Virtual Care
- Health equity
Medtronic and Viz.ai Partner to Improve Stroke Care with AI
The technology could decrease time to stroke treatment.
Stroke is the leading cause of disability in the U.S. and death outside the country. The medical condition requires emergency care and can lead to brain damage, disability and death. But a partnership announced today between Medtronic and Viz.ai aims to help decrease time to stroke treatment and improve patient outcomes.
Viz.ai’s platform uses artificial intelligence (AI) to identify suspected large occlusion strokes and automatically notify specialists. The technology connects to computed tomography (CT) scanners in hospitals and alerts specialists within minutes when a stroke is identified. Radiological images are sent to specialists’ smartphones, so they can provide treatment as soon as possible.
“Viz.ai allows clinicians to receive an alert for suspected large vessel occlusion and the corresponding visual data,” said Elad Levy, M.D., chairman in the neurosurgery department with the University at Buffalo’s Jacobs School of Medicine and Biomedical Sciences. “The combination of AI-powered alerts, mobile image viewing and HIPAA-compliant communication facilitates synchronization of stroke care with great potential to impactfully reduce door-to-needle time and help an increased number of patients.”
Through the partnership, Medtronic, a medical technology company, will distribute Viz.ai’s large vessel occlusion detection and triage software services.
“We are excited about this partnership because Viz.ai’s technology has the potential to significantly reduce the time it takes for patients suspected of (large vessel occlusion) stroke to receive the care they need,” said Stacey Pugh, vice president and general manager of Medtronic’s neurovascular business. “Viz.ai’s software coupled with our network is going to increase access to needed therapies.”
The clinical decision support software is the first of its kind to be cleared by the U.S. Food and Drug Administration, according to Viz.ai.
But other FDA-cleared technologies, like iSchemaView’s RAPID, also use AI to aid clinicians in diagnosing and treating stroke victims more quickly.
Viz.ai’s technology is available in more than 200 hospitals.
Get the best insights in digital health directly to your inbox.
Related
IBM Develops Virtual Assistant to Aid Stroke Patients
Kaiser Permanente Is Using Telemedicine to Speed Up Stroke Treatment
The Clinical Divide: Ensuring Top Treatment for Stroke Victims
